New immune cell therapy targets Hard-to-Treat leukemia in early trial

NCT ID NCT07556757

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participants aged 12 and older will receive the treatment to check its safety and see if it helps control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia leukemia precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-ALL LEUKEMIA

Contacts and locations

Locations

Alberts Cellular Therapy
RECRUITING

Pretoria, 0044, South Africa
Dr Jackie Thomson Inc
RECRUITING

Johannesburg, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.